Burden Of Long-Term Morbidity Borne By Survivors Of Acute Myeloid Leukemia (Aml) Treated With Blood Or Marrow Transplantation (Bmt) - A Report From The Bmt Survivor Study (Bmtss)

Background: BMT is now an integral part of consolidation and/or salvage for patients with AML. With the growing population survivors, there is a need to understand the quality of survival. This would allow for appropriate resource allocation and implementation of risk-based screening for early detection of chronic health conditions over time. Yet, a comprehensive evaluation of the long-term burden of morbidity borne by AML patients treated with BMT remains unknown. We addressed this gap by evaluating long-term severe/life-threatening/fatal chronic health conditions (CHCs) in AML patients treated with BMT using the BMTSS.